Who Buys Cefpodoxime from India — 442 Importers Behind a $79.5M Market
India's cefpodoxime import market is served by 442 active buyers who collectively imported $79.5M across 1,734 shipments. AMICI PHARMACEUTICALS (UNITED STATES) leads with a 33.9% market share, followed by CRONUS PHARMA LLC and CRONUS PHARMA LLC,. The top 5 buyers together control 52.3% of total import value, reflecting a moderately competitive buyer landscape.
Cefpodoxime buyer data — 442 importers · $79.5M market · 1,734 shipmentsTransData Nexus · Indian Customs Data
Top Cefpodoxime Importers — Ranked by Import Value
AMICI PHARMACEUTICALS (UNITED STATES) is the leading cefpodoxime importer from India, holding a 33.9% share of the $79.5M market across 1,734 shipments from 442 buyers. The top 5 buyers — AMICI PHARMACEUTICALS (UNITED STATES), CRONUS PHARMA LLC (UNITED STATES), CRONUS PHARMA LLC, (UNITED STATES), ALKALOID AD SKOPJE (NORTH MACEDONIA), MCKESSON THIRD PARTY LOGISTICS (UNITED STATES) — collectively control 52.3% of total import value.
Top Cefpodoxime Buyers & Importers
Ranked by import value · 442 active buyers · Indian Customs (DGFT) data
Mar 2026
Top Cefpodoxime Buyers & Importers — Ranked by Import Value. 442 active buyers with import value, shipments, country and supplier data compiled from Indian Customs records by TransData Nexus.
#
Buyer & Formulations
Value
Orders
Suppliers
Share
1
AMICI PHARMACEUTICALSUNITED STATES
·
Updated
·HS 30042019
CEFPO PROX. TABLETS USP 200MG [970 X 500'S]CEFPODOXIME PROXETIL TABLETS 200MGCEFPODOXIME PROXETIL TABLETS 200MG NOS
Which companies are buying Cefpodoxime — and from which countries?
Flow of Cefpodoxime exports from India: each country's share and the named importers behind the numbers
Cefpodoxime — Buyer Countries to Key Importers
Trade flow: top importing countries → named buyer companies
Top 5 importing countries account for 85.2% of global Cefpodoxime imports — led by United States (69.6%) with a total trade value of $79.5M across 1,734 shipments from India.
Market Analysis: Top Importing Countries & Their Importers
1United States
United States emerges as the first largest importing country, achieving a total trade value of $55.3M through 185 shipments. This represents a market share of 69.6% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: United States has a diverse importer base, with their top importers including:
• AMICI PHARMACEUTICALS - $27.0M (48.7% of country's total business)
• CRONUS PHARMA LLC - $5.5M (10.0% of country's total business)
• CRONUS PHARMA LLC, - $4.0M (7.3% of country's total business)
• MCKESSON THIRD PARTY LOGISTICS - $2.5M (4.6% of country's total business)
• AUROLOGISTICS LLC, (AUROBINDO PHARM - $2.3M (4.2% of country's total business)
• Rest of United States's importers - $14.0M (25.3% of country's total business)
Key Insight: United States demonstrates strong market positioning with an average shipment value of $299.0K, indicating premium pricing strategy compared to the market average of $45.9K.
United States is a key market for Cefpodoxime imports, representing 69.6% of total trade value.
The importation of Cefpodoxime from India involves various buyer segments, each with distinct purchasing behaviors:
Distributors: Entities like AMICI Pharmaceuticals and Cronus Pharma LLC in the United States function as intermediaries, procuring large quantities of Cefpodoxime to supply to healthcare providers and pharmacies. Their purchasing patterns are characterized by bulk orders to leverage economies of scale, ensuring a steady supply chain to meet market demand.
Contract Manufacturers: Companies such as Aurobindo Pharma USA, Inc. and its logistics arm, AuroLogistics LLC, import Cefpodoxime for further processing or formulation. These entities typically place consistent, sizable orders aligned with their production schedules to maintain uninterrupted manufacturing operations.
Hospital Groups and Retail Chains: While not explicitly listed among the top buyers, these organizations often procure Cefpodoxime through distributors. Their purchasing behavior is driven by patient demand, leading to regular, moderate-sized orders to ensure availability without overstocking.
Government Procurement Agencies: In countries like Sudan and Vietnam, government bodies may import Cefpodoxime directly or through tenders to supply public healthcare facilities. Their procurement is often characterized by large, periodic orders aligned with national healthcare programs and budget cycles.
Import regulations for Cefpodoxime vary across the top importing countries:
United States:
Regulatory Authority: U.S. Food and Drug Administration (FDA).
Import Registration Process: Importers must ensure that Cefpodoxime is FDA-approved. This involves submitting an Abbreviated New Drug Application (ANDA) for generic drugs, demonstrating bioequivalence to the brand-name counterpart.
Estimated Timeline for Registration: The ANDA review process typically takes 10 months, though it can vary based on the completeness of the application and FDA workload.
Import Tariff/Duty for HS 30042019: According to U.S. Customs Ruling NY N010042, Cefpodoxime imported in bulk form under subheading 2941.90.5000 of the Harmonized Tariff Schedule of the United States (HTSUS) is duty-free.
The demand for Cefpodoxime in importing countries is influenced by several key factors:
Disease Prevalence: Cefpodoxime is a broad-spectrum cephalosporin antibiotic effective against various bacterial infections, including respiratory tract infections, skin infections, and urinary tract infections. High prevalence of these conditions in certain regions drives the need for effective antibiotic treatments.
Government Healthcare Programs and Universal Health Coverage Expansion: Many countries are expanding their healthcare programs to achieve universal health coverage, increasing access to essential medicines. This expansion often includes the procurement of antibiotics like Cefpodoxime to treat common infections.
WHO Essential Medicines List Procurement: Cefpodoxime is included in the WHO Model List of Essential Medicines, which guides countries in selecting medicines that meet priority healthcare needs. Inclusion in this list encourages countries to procure Cefpodoxime to ensure availability in public health systems. (who.int)
Tender-Based Purchasing: Many governments and large healthcare organizations procure medicines through tender processes to ensure cost-effectiveness and supply security. Cefpodoxime's inclusion in national essential medicines lists makes it a common subject of such tenders, influencing purchasing patterns and market dynamics.
Common Questions — Cefpodoxime Buyers & Importers
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
QWho is the largest cefpodoxime buyer importing from India?
Based on import volume and value, AMICI PHARMACEUTICALS (UNITED STATES) leads with $27.0M in imports and a 33.9% market share — the highest of any single cefpodoxime importer. CRONUS PHARMA LLC (UNITED STATES) and CRONUS PHARMA LLC, (UNITED STATES) are the next largest buyers.
QHow many companies buy cefpodoxime from India?
There are 442 active cefpodoxime buyers importing from India, with a combined market of $79.5M across 1,734 shipments to 78 countries. The top 5 buyers hold 52.3% of total import value, while the remaining 437 buyers handle the other 47.7%.
QWhich countries import the most cefpodoxime from India?
The top importing countries for cefpodoxime from India are United States (69.6%), France (5.8%), Sudan (3.8%), Vietnam (3.2%), Macedonia,the Former Yugoslav Republic Of (2.8%). These markets represent the largest demand centres for Indian pharmaceutical exports of cefpodoxime, with buyers ranging from government procurement agencies to private pharmaceutical distributors.
QWhat is the average import order value for cefpodoxime from India?
The average import transaction value for cefpodoxime from India is , with an average unit price of . Order sizes vary significantly based on buyer type — government tenders tend to be larger while private distributors place more frequent smaller orders.
The importation of Cefpodoxime from India involves various buyer segments, each with distinct purchasing behaviors:
Distributors: Entities like AMICI Pharmaceuticals and Cronus Pharma LLC in the United States function as intermediaries, procuring large quantities of Cefpodoxime to supply to healthcare providers and pharmacies. Their purchasing patterns are characterized by bulk orders to leverage economies of scale, ensuring a steady supply chain to meet market demand.
Contract Manufacturers: Companies such as Aurobindo Pharma USA, Inc. and its logistics arm, AuroLogistics LLC, import Cefpodoxime for further processing or formulation. These entities typically place consistent, sizable orders aligned with their production schedules to maintain uninterrupted manufacturing operations.
Hospital Groups and Retail Chains: While not explicitly listed among the top buyers, these organizations often procure Cefpodoxime through distributors. Their purchasing behavior is driven by patient demand, leading to regular, moderate-sized orders to ensure availability without overstocking.
Government Procurement Agencies: In countries like Sudan and Vietnam, government bodies may import Cefpodoxime directly or through tenders to supply public healthcare facilities. Their procurement is often characterized by large, periodic orders aligned with national healthcare programs and budget cycles.
Import regulations for Cefpodoxime vary across the top importing countries:
United States:
Regulatory Authority: U.S. Food and Drug Administration (FDA).
Import Registration Process: Importers must ensure that Cefpodoxime is FDA-approved. This involves submitting an Abbreviated New Drug Application (ANDA) for generic drugs, demonstrating bioequivalence to the brand-name counterpart.
Estimated Timeline for Registration: The ANDA review process typically takes 10 months, though it can vary based on the completeness of the application and FDA workload.
Import Tariff/Duty for HS 30042019: According to U.S. Customs Ruling NY N010042, Cefpodoxime imported in bulk form under subheading 2941.90.5000 of the Harmonized Tariff Schedule of the United States (HTSUS) is duty-free.
The demand for Cefpodoxime in importing countries is influenced by several key factors:
Disease Prevalence: Cefpodoxime is a broad-spectrum cephalosporin antibiotic effective against various bacterial infections, including respiratory tract infections, skin infections, and urinary tract infections. High prevalence of these conditions in certain regions drives the need for effective antibiotic treatments.
Government Healthcare Programs and Universal Health Coverage Expansion: Many countries are expanding their healthcare programs to achieve universal health coverage, increasing access to essential medicines. This expansion often includes the procurement of antibiotics like Cefpodoxime to treat common infections.
WHO Essential Medicines List Procurement: Cefpodoxime is included in the WHO Model List of Essential Medicines, which guides countries in selecting medicines that meet priority healthcare needs. Inclusion in this list encourages countries to procure Cefpodoxime to ensure availability in public health systems. (who.int)
Tender-Based Purchasing: Many governments and large healthcare organizations procure medicines through tender processes to ensure cost-effectiveness and supply security. Cefpodoxime's inclusion in national essential medicines lists makes it a common subject of such tenders, influencing purchasing patterns and market dynamics.
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
2France
France emerges as the second largest importing country, achieving a total trade value of $4.6M through 55 shipments. This represents a market share of 5.8% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: France has a diverse importer base, with their top importers including:
• CENTRE SPECIALITIES PHARMACEUTIQUES - $1.2M (26.0% of country's total business)
• CSPM - $1.0M (22.7% of country's total business)
Key Insight: France demonstrates strong market positioning with an average shipment value of $84.0K, indicating premium pricing strategy compared to the market average of $45.9K.
France is a key market for Cefpodoxime imports, representing 5.8% of total trade value.
Primary Market
Secondary Market
3Sudan
Sudan emerges as the third largest importing country, achieving a total trade value of $3.1M through 6 shipments. This represents a market share of 3.8% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Sudan has a diverse importer base, with their top importers including:
• AMDWYR FOR IMPORT AND EXPORT - $863.0K (28.2% of country's total business)
Key Insight: Sudan demonstrates strong market positioning with an average shipment value of $509.2K, indicating premium pricing strategy compared to the market average of $45.9K.
Sudan is a key market for Cefpodoxime imports, representing 3.8% of total trade value.
Primary Market
Secondary Market
4Vietnam
Vietnam emerges as the fourth largest importing country, achieving a total trade value of $2.6M through 0 shipments. This represents a market share of 3.2% of the total market activity, demonstrating their significant presence in the industry.
Key Insight: Vietnam demonstrates strong market positioning with an average shipment value of $2.6M, indicating premium pricing strategy compared to the market average of $45.9K.
Vietnam is a key market for Cefpodoxime imports, representing 3.2% of total trade value.
Primary Market
Secondary Market
5Macedonia,the Former Yugoslav Republic Of
Macedonia,the Former Yugoslav Republic Of emerges as the fifth largest importing country, achieving a total trade value of $2.2M through 0 shipments. This represents a market share of 2.8% of the total market activity, demonstrating their significant presence in the industry.
Key Insight: Macedonia,the Former Yugoslav Republic Of demonstrates strong market positioning with an average shipment value of $2.2M, indicating premium pricing strategy compared to the market average of $45.9K.
Macedonia,the Former Yugoslav Republic Of is a key market for Cefpodoxime imports, representing 2.8% of total trade value.
Primary Market
Secondary Market
Re-exporters: Some buyers may import Cefpodoxime with the intent to re-export to neighboring regions, capitalizing on price differentials and market demands. Their purchasing patterns can be irregular, influenced by market opportunities and regulatory environments.
Understanding these segments and their purchasing behaviors is crucial for suppliers aiming to tailor their strategies to meet the specific needs and expectations of each buyer category.
TransData Nexus Research · Government and regulatory sourcesMar 2026
Regulatory Authority: Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM).
Import Registration Process: Importers must obtain a Marketing Authorization (MA) from ANSM, which requires submission of a dossier including quality, safety, and efficacy data.
Estimated Timeline for Registration: The MA process can take up to 210 days, subject to the completeness of the application and any additional information requests.
Import Tariff/Duty for HS 30042019: As a member of the European Union, France applies the EU Common External Tariff. For HS code 30042019, the duty is typically 0%, but importers should verify current rates with French customs authorities.
Sudan:
Regulatory Authority: National Medicines and Poisons Board (NMPB).
Import Registration Process: Importers must register pharmaceutical products with the NMPB, providing documentation on product quality, safety, and efficacy.
Estimated Timeline for Registration: The registration process can take approximately 6 to 12 months, depending on the completeness of the submission and regulatory review.
Import Tariff/Duty for HS 30042019: Import duties for pharmaceuticals in Sudan can vary; importers should consult the Sudanese Customs Authority for the most current rates.
Vietnam:
Regulatory Authority: Drug Administration of Vietnam (DAV).
Import Registration Process: Importers are required to obtain a Marketing Authorization from the DAV, which involves submitting a comprehensive dossier including clinical data and manufacturing standards.
Estimated Timeline for Registration: The process typically takes 12 to 18 months, subject to the completeness of the application and any additional information requests.
Import Tariff/Duty for HS 30042019: Vietnam's import duties for pharmaceuticals under HS code 30042019 are generally low, often ranging from 0% to 5%, but importers should verify current rates with Vietnamese customs authorities.
North Macedonia:
Regulatory Authority: Agency for Medicines and Medical Devices (MALMED).
Import Registration Process: Importers must obtain a Marketing Authorization from MALMED, requiring submission of documentation on product quality, safety, and efficacy.
Estimated Timeline for Registration: The registration process can take approximately 6 to 12 months, depending on the completeness of the submission and regulatory review.
Import Tariff/Duty for HS 30042019: Import duties for pharmaceuticals in North Macedonia are typically low; importers should consult the Customs Administration of North Macedonia for the most current rates.
Importers are advised to consult the respective regulatory authorities and customs agencies for the most current and detailed information, as regulations and tariffs are subject to change.
TransData Nexus Research · Government and regulatory sourcesMar 2026
With 442 buyers across 78 countries, the global market for Cefpodoxime is substantial. Suppliers can capitalize on this demand by aligning with national healthcare priorities, participating in tender processes, and ensuring compliance with regulatory standards to effectively meet the needs of diverse markets.
TransData Nexus Research · Government and regulatory sourcesMar 2026
$45.9K
$2.74 per unit
Re-exporters: Some buyers may import Cefpodoxime with the intent to re-export to neighboring regions, capitalizing on price differentials and market demands. Their purchasing patterns can be irregular, influenced by market opportunities and regulatory environments.
Understanding these segments and their purchasing behaviors is crucial for suppliers aiming to tailor their strategies to meet the specific needs and expectations of each buyer category.
TransData Nexus Research · Government and regulatory sourcesMar 2026
Regulatory Authority: Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM).
Import Registration Process: Importers must obtain a Marketing Authorization (MA) from ANSM, which requires submission of a dossier including quality, safety, and efficacy data.
Estimated Timeline for Registration: The MA process can take up to 210 days, subject to the completeness of the application and any additional information requests.
Import Tariff/Duty for HS 30042019: As a member of the European Union, France applies the EU Common External Tariff. For HS code 30042019, the duty is typically 0%, but importers should verify current rates with French customs authorities.
Sudan:
Regulatory Authority: National Medicines and Poisons Board (NMPB).
Import Registration Process: Importers must register pharmaceutical products with the NMPB, providing documentation on product quality, safety, and efficacy.
Estimated Timeline for Registration: The registration process can take approximately 6 to 12 months, depending on the completeness of the submission and regulatory review.
Import Tariff/Duty for HS 30042019: Import duties for pharmaceuticals in Sudan can vary; importers should consult the Sudanese Customs Authority for the most current rates.
Vietnam:
Regulatory Authority: Drug Administration of Vietnam (DAV).
Import Registration Process: Importers are required to obtain a Marketing Authorization from the DAV, which involves submitting a comprehensive dossier including clinical data and manufacturing standards.
Estimated Timeline for Registration: The process typically takes 12 to 18 months, subject to the completeness of the application and any additional information requests.
Import Tariff/Duty for HS 30042019: Vietnam's import duties for pharmaceuticals under HS code 30042019 are generally low, often ranging from 0% to 5%, but importers should verify current rates with Vietnamese customs authorities.
North Macedonia:
Regulatory Authority: Agency for Medicines and Medical Devices (MALMED).
Import Registration Process: Importers must obtain a Marketing Authorization from MALMED, requiring submission of documentation on product quality, safety, and efficacy.
Estimated Timeline for Registration: The registration process can take approximately 6 to 12 months, depending on the completeness of the submission and regulatory review.
Import Tariff/Duty for HS 30042019: Import duties for pharmaceuticals in North Macedonia are typically low; importers should consult the Customs Administration of North Macedonia for the most current rates.
Importers are advised to consult the respective regulatory authorities and customs agencies for the most current and detailed information, as regulations and tariffs are subject to change.
TransData Nexus Research · Government and regulatory sourcesMar 2026
With 442 buyers across 78 countries, the global market for Cefpodoxime is substantial. Suppliers can capitalize on this demand by aligning with national healthcare priorities, participating in tender processes, and ensuring compliance with regulatory standards to effectively meet the needs of diverse markets.
TransData Nexus Research · Government and regulatory sourcesMar 2026
Analysis Methodology
1.Buyer Identification: 442 global importers of Cefpodoxime identified from consignee fields in DGFT shipping bill records.
2.Import Value Analysis: Total import value aggregated from 1,734 individual shipping bill records. Values are FOB in USD.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
4.Geographic Distribution: Buyer imports distributed across 78 destination countries with market share per buyer calculated from capped values.
